Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

11149	Companies
245964	Keywords
173948	Articles
132749	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 1 year ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 1 year ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 1 year ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 1 year ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 1 year 1 month ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 1 year 1 month ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 1 year 1 month ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 1 year 1 month ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 1 year 1 month ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 1 year 1 month ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 10/08/2026 at 22:05, 3 hours 32 minutes ago

Rochon Family Executes Additional Strategic Purchase of $26.8 Million of AIAI Holdings Shares
Published on 10/08/2026 at 20:30, 5 hours 7 minutes ago

Guanajuato Silver Completes San Ignacio to Bolanitos Connection Tunnel
Published on 10/08/2026 at 14:31, 11 hours 6 minutes ago

First Breach Expands Hiring Initiative to Support Ammunition Production Growth and Planned Drone Manufacturing Operations
Published on 10/08/2026 at 14:30, 11 hours 7 minutes ago

Predictiv AI's Shift AI Completes AWS Foundational Technical Review and Expands Aviation Visibility Through AWS Solutions Library
Published on 10/08/2026 at 14:00, 11 hours 37 minutes ago

Earthwise Minerals Appoints Andy Randell, P.Geo., to Board of Directors

View all ACCESSWIRE

EQS Group

Published on 10/08/2026 at 20:10, 5 hours 27 minutes ago

EQS-Adhoc: Westwing Group SE: Westwing Approves Share Buyback
Published on 10/08/2026 at 19:01, 6 hours 36 minutes ago

LightOn dévoile LightOnOCR-3, une famille de modèles de référence mondiale en intelligence documentaire.
Published on 10/08/2026 at 19:01, 6 hours 36 minutes ago

LightOn releases LightOnOCR-3, a world-leading model family for document intelligence.
Published on 10/08/2026 at 18:57, 6 hours 40 minutes ago

Alkagesta Reports Record First-Half 2026 Results Across Global Trading Platform
Published on 10/08/2026 at 18:30, 7 hours 7 minutes ago

FLORENTAISE: PUBLICATION DES COMPTES CONSOLIDÉS 2024-2025 DE FLORENTAISE ET CONVOCATION DE L’ASSEMBLEE GENERALE DES ACTIONNAIRES

Les Echos

Published on 10/08/2026 at 18:30, 7 hours 7 minutes ago

Cegedim: Release of its 2026 Interim Financial Report
Published on 10/08/2026 at 18:30, 7 hours 7 minutes ago

Cegedim : Publication du Rapport Financier Semestriel 2026
Published on 10/08/2026 at 18:00, 7 hours 37 minutes ago

SMTPC - Communiqué sur le Chiffre d'affaires du 3ème trimestre 2026
Published on 10/08/2026 at 18:00, 7 hours 37 minutes ago

Launch of LINK, the next generation of THIN: Clinityx’s first European Health Data Warehouse, approved by the French Data Protection Authority for 10 years
Published on 10/08/2026 at 18:00, 7 hours 37 minutes ago

Lancement de LINK, la nouvelle génération de THIN : Le premier Entrepôt de Données de Santé européen de Clinityx, validé par la CNIL pour 10 ans

View all LES ECHOS COMFI WIRE